ANESIDORA'S JAR TAKING THE LID OFF ALL GOOD FORMULATIONS
DEAD

Serial Number

77358724

Owner

Thompson, Sharon G.

Attorney

Jordan D. Glass

First Use Date

Aug 1, 2007

Filing Date

Dec 21, 2007

Add to watchlist:

No watchlists yet
View on USPTO

ANESIDORA'S JAR TAKING THE LID OFF ALL GOOD FORMULATIONS Trademark

Serial Number: 77358724 • Registration: 3484131

ANESIDORA'S JAR TAKING THE LID OFF ALL GOOD FORMULATIONS is a trademark filed by Thompson, Sharon G. on December 21, 2007. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Thompson, Sharon G.

11 Potter Lane
Halesite, NY 117432142

Entity Type: 01

Trademark Details

Filing Date

December 21, 2007

Registration Date

August 12, 2008

First Use Anywhere

August 1, 2007

First Use in Commerce

December 1, 2007

Published for Opposition

May 27, 2008

Cancellation Date

March 13, 2015

Goods & Services

Almond oil for pharmaceutical purposes; Almond oils for pharmaceutical purposes; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Antimicrobial preservatives for cosmetics and pharmaceuticals; Astringents; Bismuth preparations for pharmaceutical purposes; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Gelatin capsules sold empty for pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of muscle soreness; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Injectable pharmaceuticals for treatment of anaphylactic reactions; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes,and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of hormone replacement; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely,appetite suppressants; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Plant extracts for medical, veterinary and pharmaceutical purposes; Potassium preparations for pharmaceutical purposes; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Synthetic peptides for pharmaceutical purposes; Syringes sold filled with hormone replacement therapy; Unit dose capsules sold empty for pharmaceutical use; Vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry; Yeast or yeast extracts for medical, veterinary or pharmaceutical purposes

Filing History

CANCELLED SEC. 8 (6-YR)
Mar 13, 2015 C8..
REGISTERED-PRINCIPAL REGISTER
Aug 12, 2008 R.PR
PUBLISHED FOR OPPOSITION
May 27, 2008 PUBO
NOTICE OF PUBLICATION
May 7, 2008 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 21, 2008 PREV
ASSIGNED TO LIE
Apr 9, 2008 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 31, 2008 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 31, 2008 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 31, 2008 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 31, 2008 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 31, 2008 CNEA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Mar 29, 2008 GPRN
PRIORITY ACTION E-MAILED
Mar 29, 2008 GPRA
PRIORITY ACTION WRITTEN
Mar 29, 2008 CPRA
ASSIGNED TO EXAMINER
Mar 26, 2008 DOCK
NEW APPLICATION ENTERED
Dec 28, 2007 NWAP